Go Pro
NASDAQ:FENC

Adherex Technologies Q2 2026 Earnings Report

Adherex Technologies logo
$9.99 -0.16 (-1.58%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$9.98 -0.02 (-0.15%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adherex Technologies EPS Results

Actual EPS
N/A
Consensus EPS
$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

Adherex Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$16.21 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adherex Technologies Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Adherex Technologies Earnings Headlines

Fennec Announces Results of Annual Meeting
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
See More Adherex Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adherex Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adherex Technologies and other key companies, straight to your email.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies (NASDAQ:FENC) and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

View Adherex Technologies Profile